Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $71.56 (-11.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 2, 2026 | William Pickering | Tudor Pickering | $35.00 | -51.1% |
| Dec 17, 2025 | Edward Tenthoff | Piper Sandler | $100.00 | +39.7% |
| Nov 29, 2024 | William Pickering | Bernstein | $24.00 | -66.5% |
| Nov 27, 2024 | Keay Nakae | Loop Capital Markets | $29.97 | -58.1% |
| Sep 3, 2024 | David Lebowitz | Citigroup | $27.00 | -62.3% |
| Jul 5, 2024 | Patrick Trucchio | H.C. Wainwright | $29.97 | -58.1% |
| Jun 5, 2024 | Andrea Tan | Goldman Sachs | $31.00 | -56.7% |
| May 30, 2024 | Luca Issi | RBC Capital | $24.98 | -65.1% |
| Jan 19, 2022 | Madhu Kumar | Goldman Sachs | $85.00 | +18.8% |
Top Analysts Covering ARWR
ARWR vs Sector & Market
| Metric | ARWR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.12 | 2.25 | 2.42 |
| Analyst Count | 17 | 8 | 18 |
| Target Upside | +26.1% | +16187.2% | +19.5% |
| P/E Ratio | 51.38 | 3.74 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $31M | $79M | $145M | 4 |
| 2026-12-31 | $17M | $43M | $78M | 4 |
| 2027-03-31 | $12M | $31M | $57M | 4 |
| 2027-06-30 | $13M | $34M | $62M | 3 |
| 2027-09-30 | $63M | $158M | $290M | 3 |
| 2028-09-30 | $524M | $549M | $573M | 8 |
| 2029-09-30 | $549M | $886M | $1.26B | 4 |
| 2030-09-30 | $1.08B | $1.75B | $2.48B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-2.26 | $-1.08 | $-0.23 | 3 |
| 2026-12-31 | $-2.84 | $-1.36 | $-0.29 | 6 |
| 2027-03-31 | $-3.05 | $-1.46 | $-0.31 | 3 |
| 2027-06-30 | $-3.10 | $-1.49 | $-0.32 | 5 |
| 2027-09-30 | $-1.59 | $-0.76 | $-0.16 | 3 |
| 2028-09-30 | $-4.09 | $-2.81 | $-1.09 | 7 |
| 2029-09-30 | $-1.96 | $-1.27 | $-0.64 | 2 |
| 2030-09-30 | $1.83 | $3.64 | $5.61 | 5 |
Frequently Asked Questions
What is the analyst consensus for ARWR?
The consensus among 17 analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) is Buy with an average price target of $91.00.
What is the highest price target for ARWR?
The highest price target for ARWR is $100.00, set by Edward Tenthoff at Piper Sandler on 2025-12-17.
What is the lowest price target for ARWR?
The lowest price target for ARWR is $24.00, set by William Pickering at Bernstein on 2024-11-29.
How many analysts cover ARWR?
17 analysts have issued ratings for Arrowhead Pharmaceuticals, Inc. in the past 12 months.
Is ARWR a buy or sell right now?
Based on 17 analyst ratings, ARWR has a consensus rating of Buy (2.12/5) with a +26.1% upside to the consensus target of $91.00.
What are the earnings estimates for ARWR?
Analysts estimate ARWR will report EPS of $-1.08 for the period ending 2026-09-30, with revenue estimated at $79M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.